MARKET

AORT

AORT

Cryolife Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

18.84
+0.77
+4.26%
After Hours: 18.84 0 0.00% 16:01 05/20 EDT
OPEN
18.45
PREV CLOSE
18.07
HIGH
18.99
LOW
18.25
VOLUME
205.31K
TURNOVER
0
52 WEEK HIGH
31.78
52 WEEK LOW
15.44
MARKET CAP
757.40M
P/E (TTM)
-46.6915
1D
5D
1M
3M
1Y
5Y
Artivion to Participate in the UBS 2022 Global Healthcare Conference
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in the upcoming UBS 2022 Global Healthcare Conference on Monday, May 23, 2022 at the Lotte New York Palace. The ...
PR Newswire · 4d ago
Further weakness as Artivion (NYSE:AORT) drops 24% this week, taking three-year losses to 48%
Many investors define successful investing as beating the market average over the long term. But in any portfolio...
Simply Wall St. · 05/12 18:55
--Needham Trims Artivion's Price Target to $29 From $30, Reiterates Buy Rating
MT Newswires · 05/06 06:37
Artivion Non-GAAP EPS of $0.03, revenue of $77.2M
Artivion press release (NYSE:AORT): Q1 Non-GAAP EPS of $0.03. Revenue of $77.2M (+8.6% Y/Y). For FY22, the company continues to expect constant currency revenue growth of between 9.0% and 11.0%,
Seekingalpha · 05/05 20:46
Artivion Q1 EPS $0.03 Beats $(0.12) Estimate, Sales $77.20M Beat $74.85M Estimate; Sees FY22 Sales Growth 9-11% Year Over Year
Artivion (NYSE:AORT) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.12) by 125 percent. This is unchanged from the same period last year. The company reported quarterly
Benzinga · 05/05 20:38
-- Earnings Flash (AORT) ARTIVION Reports Q1 EPS $0.03, vs. Street Est of $-0.01
MT Newswires · 05/05 16:26
-- Earnings Flash (AORT) ARTIVION Reports Q1 Revenue $77.2M, vs. Street Est of $74.9M
MT Newswires · 05/05 16:21
ArtivionAnnounces Release Date and Teleconference Call Details for First Quarter 2022 Financial Results
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2022 financial results will be released on Thursday, May 5, 2022 after the market closes. On that day, the Company wil...
PR Newswire · 04/21 12:25
More
No Data
Learn about the latest financial forecast of AORT. Analyze the recent business situations of Cryolife Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

60.00%Strong Buy
20.00%Buy
20.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AORT stock price target is 28.20 with a high estimate of 35.00 and a low estimate of 23.00.
High35.00
Average28.20
Low23.00
Current 18.84
EPS
Actual
Estimate
-0.34-0.18-0.010.16
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 198
Institutional Holdings: 35.90M
% Owned: 89.30%
Shares Outstanding: 40.20M
TypeInstitutionsShares
Increased
37
1.10M
New
15
447.51K
Decreased
52
846.92K
Sold Out
16
229.38K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.35%
Healthcare Equipment & Supplies
+0.36%
Key Executives
Chairman/President/Chief Executive Officer/Director
James Mackin
Chief Financial Officer/Chief Operating Officer/Executive Vice President
D. Ashley Lee
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Jean Holloway
Senior Vice President/Director of Sales/Director of Marketing
John Davis
Senior Vice President
Marshall Stanton
Chief Accounting Officer/Vice President
Amy Horton
Vice President - Operations
Dennis Maier
Vice President/Director of Human Resources
Matthew Getz
Vice President
F. Peter Barthold
Vice President
Andrew Green
Vice President
Rochelle Maney
Lead Director/Independent Director
Jeffrey Burbank
Independent Director
Thomas Ackerman
Independent Director
Daniel Bevevino
Independent Director
Marna Borgstrom
Independent Director
James Bullock
Independent Director
Jon Salveson
Independent Director
Anthony Semedo
No Data
No Data
About AORT
Artivion, Inc. (Artivion), formerly CryoLife, Inc., is a medical device company. The Company is focused on developing various solutions that address cardiac and vascular surgeons' challenges in treating patients with aortic diseases. The Company's four groups of products include aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. Artivion's cryopreserved cardiac and vascular allograft tissues help in restoring surgeries for adults and pediatric patients. It offers surgical sealant through BioGlue product. Its surgical aortic valve replacement solutions include On-X Aortic Heart Valves and CryoValve SG Pulmonary Valve Allograft for the Ross procedure. The Company's mitral valve solutions include Chord-X for mitral valve repair and On-X Mitral Heart Valve. Artivion's Cardiac and Vascular Ancillary solutions provide complementary support for the patient's cardiac and vascular surgical procedures.

Webull offers kinds of Artivion Inc stock information, including NYSE:AORT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AORT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AORT stock methods without spending real money on the virtual paper trading platform.